Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Aldo P. Maggioni; John J.V. McMurray; Jeffrey L. Probstfield; Matthew C. Riddle; Scott D. Solomon; Jean‐Claude Tardif; Marc A. Pfeffer; Brian Claggett; Rafael Díaz; Kenneth Dickstein; Hertzel C. Gerstein; Lars Køber; Francesca Lawson; Lin Ping; Xiaodan Wei; Eldrin F. Lewis

doi:10.1056/nejmoa1509225

Abstract

In patients with type 2 diabetes and a recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular events or other serious adverse events. (Funded by Sanofi; ELIXA ClinicalTrials.gov number, NCT01147250.).

Keywords

LixisenatideAcute coronary syndromeType 2 diabetesMedicineInternal medicineCardiologyDiabetes mellitusMyocardial infarctionEndocrinology

Affiliated Institutions

Related Publications

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

William B. White , Christopher P. Cannon , Simon Heller +10 more

Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor al...

2013 New England Journal of Medicine 2475 citations

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green , M. Angelyn Bethel , Paul W. Armstrong +16 more

Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular ...

2015 New England Journal of Medicine 2519 citations

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Gregory G. Schwartz , Philippe Gabríel Steg , Michael Szarek +19 more

Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower am...

2018 New England Journal of Medicine 3201 citations

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

Stephen D. Wiviott , Eugene Braunwald , Carolyn H. McCabe +11 more

In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events...

2007 New England Journal of Medicine 6636 citations

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

John H. Alexander , Renato D. Lópes , Stefan James +31 more

The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding ev...

2011 New England Journal of Medicine 990 citations

Publication Info

Year: 2015
Type: article
Volume: 373
Issue: 23
Pages: 2247-2257
Citations: 2220
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2220

OpenAlex

Cite This

APA Style

                            
                                
                                    Aldo P. Maggioni, 
                                
                                    John J.V. McMurray, 
                                
                                    Jeffrey L. Probstfield
                                
                                et al.
                            
                            (2015). 
                            Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. 
                            New England Journal of Medicine
                            , 373
                            (23)
                            , 2247-2257.
                            https://doi.org/10.1056/nejmoa1509225
                        

Identifiers

DOI: 10.1056/nejmoa1509225